This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Pediatrics  • Pediatrics, Other  • Immunization  • Alert me on articles by topic  Social Bookmarking   What's this?

JAMA. 2008;299(2):166-167.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2007;56:1217-1219

On September 19, 2007, MedImmune Vaccines (Gaithersburg, Maryland) received approval from the Food and Drug Administration (FDA) to expand the use of FluMist®, a live, attenuated influenza vaccine (LAIV), to children aged 2-4 years (i.e., 24-49 months). FluMist is an intranasally administered influenza vaccine that was first licensed by the FDA in 2003 for healthy, nonpregnant persons aged 5-49 years.¹ Expanding the age indications to include healthy children aged 2-4 years provides another influenza vaccination option for young children. In granting the new approval, FDA emphasized that FluMist is not approved for vaccination of children aged <2 years or adults aged >49 years, and that FluMist safety has not been established in persons with underlying medical conditions predisposing them to influenza-related complications.² In addition, FluMist should not be administered to persons with asthma or children aged <5 years with recurrent wheezing.^1,2

New Recommendation for FluMist

In a randomized trial published in 2007, . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?